Dan grew up on the sunny West Coast in Perth where he studied medicine before moving to Sydney to train as an Immunologist at Westmead and St Vincent’s hospitals. He then undertook his PhD studies with Rob Brink at the Garvan Institute investigating memory B cell and plasma cell differentiation in antibody responses to vaccination. He’s now returned to Westmead as a Staff Specialist in Clinical Immunology and Immunopathology, but remains half-time at the Garvan to continue his research and establish new genome sequencing projects studying human autoimmune disorders.
What does the conference theme “Do More” mean to you?
It means we need to be committed and proactive in fostering education and collaboration between groups from different disciplines to ensure that we provide the world’s best evidence-based clinical practice in our service of our patients and the community.
Why are you excited about participating in MM2017?
I am participating in MM2017 to be a part of education and collaboration between clinicians, pharmacists and other disciplines to promote a greater understanding of monoclonal antibodies, which constitute the fastest growing area of new therapies for common and rare diseases.
Where do you see pharmacy in 10 years?
I see pharmacy growing to take a leading role in the safe roll-out of new drugs in both the hospital and community settings.